
Emerging Diagnostic and Treatment Opportunities for Neuroedocrine Tumors of the Gastrointestinal Tract
Recent advancements in diagnostic imaging and chemotherapeutics are reshaping management of neuroendocrine tumors (NETs). During Emerging Diagnostic and Treatment Opportunities for Neuroendocrine Tumors of the Gastrointestinal Tract, the panel presents the updated diagnosis and management of both primary and metastatic NETs in the context of these innovations and their impact on outcomes.
Target Audience
- Breast surgeons
- Cancer registrars
- Colorectal surgeons
- General surgeons
- Nurses
- Nurse practitioners
- Other advanced practice professionals
- Physician assistants
- Physicians in accredited cancer centers and programs
- Surgical oncologists
Learning Objectives
- Outline the context of these innovations for both primary and metastatic NETs.
- Discuss the impact of the changes to diagnosis and treatment on patient outcomes.
- Understand the indications and rationale for new imaging modalities and chemotherapy options for patients with gastrointestinal NETs.
Contact
- For questions about the course, please contact cancerresearchprogram@facs.org
- If you have any technical questions, contact learning@facs.org
Disclosure Information
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all financial relationships with any commercial interest (termed by the ACCME as “ineligible companies”, defined below) held in the last 24 months (see below for definitions). Please note that first authors were required to collect and submit disclosure information on behalf all other authors/contributors, if applicable.
Ineligible company
The ACCME defines an “ineligible company” as any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition.
Financial Relationships
Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
Conflict of Interest
Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship.
The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.
Speakers/Moderators/Discussants/Authors Disclosures
Clancy Clark, MD, FACS (moderator) – Nothing to disclose
Wake Forest Baptist Health
Flavio Rocha, MD, FACS, FSSO (moderator) – Nothing to disclose
Oregon Health & Science University/Knight Cancer Institute
Delphine Chen, MD (speaker) – Nothing to disclose
University of Washington/Seattle Cancer Care Alliance
Caio Max Sao Pedro Rocha Lima, MD, MS (speaker) – Nothing to disclose
Wake Forest University/Baptist Medical Center
Jonathon McConathy, MD, PhD (speaker) – honorarium and research support for consulting at Eli Lilly/Avid, honorarium for consulting at GE Healthcare, honorarium and research support for consulting at Blue Earth Diagnostics, research support for clinical trial at Cytosite Biopharma, honorarium for consulting at ImaginAb, honorarium for consulting at Canon Medical
J. Bart Rose, MD, MAS, FACS (speaker) – Nothing to disclose
University of Alabama, Birmingham
Planning Committee Disclosures
Judy Boughey, MD, FACS – Research funding support for clinical trial from Eli Lilly
Mayo Clinic
Christina Roland, MD, FACS – Research funds to institution from Bristol Myers Squibb
MD Anderson Cancer Center
Asa Carter, MBA, CTR—Nothing to disclose
American College of Surgeons
Amanda Francescatti, MS – Nothing to disclose
American College of Surgeons
Linda Zheng – Nothing to disclose
American College of Surgeons
Continuing Medical Education Credit Information
Accreditation
The American College of Surgeons is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Category 1 Credits™
The American College of Surgeons designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 CE Contact hours
- 1.00 Certificate of Completion